@article{mbs:/content/journal/jmm/10.1099/jmm.0.001007, author = "Osmanov, Ali and Wise, Andrew and Denning, David W.", title = "In vitro and in vivo efficacy of miramistin against drug-resistant fungi", journal= "Journal of Medical Microbiology", year = "2019", volume = "68", number = "7", pages = "1047-1052", doi = "https://doi.org/10.1099/jmm.0.001007", url = "https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.001007", publisher = "Microbiology Society", issn = "1473-5644", type = "Journal Article", keywords = "antifungal", keywords = "Aspergillus", keywords = "antifungal resistance", keywords = "antiseptic", keywords = "Candida", abstract = " Introduction. Miramistin is a topical antiseptic with broad antimicrobial activity that was developed in the Soviet Union during the Cold War. Aim. To investigate the antifungal activity of miramistin against clinically relevant drug-resistant fungi. Methodology. The in vitro activity of miramistin was determined following Clinical and Laboratory Standards Institute (CLSI) guidelines. Mammalian cell toxicity was tested using a McCoy cell line and topical and systemic tolerability, and in vivo efficacy was tested using Galleria mellonella models. Results. The minimal inhibitory concentration (MIC) range against fungi was 1.56–25 mg l−1 (GM 3.13 mg l−1 ). In the G. mellonella model, miramistin provided potent survival benefits for Candida albicans and Aspergillus fumigatus infection. Miramistin was tolerated by McCoy cell lines at concentrations up to 1000 mg l−1 and was systemically safe in G. mellonella at 2000 mg kg−1. Topical administration at 32 000 mg l−1 was well tolerated with no adverse effects. Conclusion. These findings support further investigation of miramistin and suggest its possible use for treatment of superficial fungal infections.", }